Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 301–400 of 799
Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia
Vicente‐Dueñas, C., González‐Herrero, I., Sehgal, L., García‐Ramírez, I., Rodríguez-Hernández, G., Pintado, B., Blanco, Ó., Criado, F. J. G., Cenador, M. B. G., Green, M. R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0192-z · Cited by 26
Okabe, S., Tauchi, T., Katagiri, S., Tanaka, Y., & Ohyashiki, K. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-37 · Cited by 30
Frietsch, J. J., Kastner, C., Grünewald, T. G. P., Schweigel, H., Nollau, P., Ziermann, J., Clement, J. H., Rosée, P. G. L., Hochhaus, A., & Butt, E. (2014) · Oncotarget · doi:10.18632/oncotarget.2072 · Cited by 25
“imatinib and nilotinib) in the treatment of CML patients [6, 7].”
BackgroundCobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia
Sh, H., Kim, S.-H., Kim, H.-J., Lee, Y., Choi, S.-Y., Park, G., Kim, J. H., Lee, A., Kim, Y., Choi, J.-M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.72 · Cited by 25
Dong, Y., Lin, Y., Gao, X., Zhao, Y., Wan, Z., Wang, H., Wei, M., Chen, X., Qin, W., Yang, G., et al. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10127-3 · Cited by 26
Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation
Liu, Y., Shao, Z., Liao, Y., Xia, X., Huang, C., He, J., Hu, T., Yu, C., Jiang, L., Liu, J., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173366 · Cited by 25
Chorzalska, A. D., Kim, J. F., Roder, K., Tepper, A., Ahsan, N., Rao, R. S. P., Olszewski, A. J., Yu, X., Terentyev, D. A., Morgan, J. W., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0262 · Cited by 26
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
Santis, S. D., Monaldi, C., Mancini, M., Bruno, S., Cavo, M., & Soverini, S. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s289306 · Cited by 30
Filipek-Gorzała, J., Kwiecińska, P., Szade, A., & Szade, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1308709 · Cited by 27
Diverging fates of cells of origin in acute and chronic leukaemia
Kovačic, B., Hoelbl‐Kovacic, A., Litos, G., Alacakaptan, M., Schuster, C., Fischhuber, K., Kerenyi, M. A., Stengl, G., Moriggl, R., Sexl, V., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100208 · Cited by 27
“Addition of cytokines that drive terminal differentiation (Zhang & Lodish, 2005) Recent and our findings suggest that BCR/ABL þ human CML stem cells might not be oncogene-addicted and therefore are not eliminated by imatinib therapy (Corbin et al, 2011).”
Up-regulatedMSI2is associated with more aggressive chronic myeloid leukemia
Kaeda, J., Ringel, F., Oberender, C., Mills, K., Quintarelli, C., Pane, F., Koschmieder, S., Slany, R. K., Schwarzer, R., Saglio, G. N., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.981175 · Cited by 26
Wongboonma, W., Thongnoppakhun, W., & Auewarakul, C. U. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.01.007 · Cited by 24
Liu, Z., Li, Y., Lv, C., Wang, L., & Song, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.047 · Cited by 25
Induction of p53 suppresses chronic myeloid leukemia
Peterson, L. F., Lo, M., Liu, Y., Giannola, D. M., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J., & Talpaz, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272682 · Cited by 25
“effective inhibition of BCR-ABL kinase activity [5].”
Pan, B., Yang, J., Wang, X., Xu, K., & Ikezoe, T. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.09.001 · Cited by 24
Yi, H. L., Than, H., Sng, C., Cheong, M. A., Chuah, C. T. H., & Xiang, W. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.06.001 · Cited by 23
Krenn, P. W., Koschmieder, S., & Fässler, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009078117 · Cited by 24
Tumor Dormancy: Long-Term Survival in a Hostile Environment
Quesnel, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-1445-2_9 · Cited by 30
Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells
Baghdadi, T. A., Abonour, R., & Boswell, H. S. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.10.003 · Cited by 27
Corbin, A. S., O'Hare, T., Gu, Z., Kraft, I. L., Eiring, A. M., Khorashad, J. S., Pomicter, A. D., Zhang, T. Y., Eide, C. A., Manley, P. W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1318 · Cited by 24
“In contrast, basal pAKT in CD34þ38 cells was low, as previously reported in BCR-ABL1–expressing murine stem cells and CD34þ38 CML cells (17, 37), unchanged upon PPY-A treatment and minimally increased by SCF alone or in combination with PPY-A (Fig.”
InfluentialSelf-citationBono, S., Lulli, M., D’Agostino, V., Gesualdo, F. D., Loffredo, R., Cipolleschi, M. G., Provenzani, A., Rovida, E., & Sbarba, P. D. (2016) · Oncotarget · doi:10.18632/oncotarget.13319 · Cited by 26
Huuhtanen, J., Ilander, M. M., Yadav, B., Dufva, O., Lähteenmäki, H., Kasanen, T., Klievink, J., Olsson‐Strömberg, U., Stentoft, J., Richter, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152585 · Cited by 26
Landberg, N., Köhnke, T., Feng, Y., Nakauchi, Y., Fan, A. C., Linde, M. H., Karigane, D., Lim, K. S., Sinha, R., Malcovati, L., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0195 · Cited by 29
p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice
Velasco-Hernández, T., Vicente‐Dueñas, C., Sánchez-García, I., & Martín-Zanca, D. (2012) · Cell Cycle · doi:10.4161/cc.23031 · Cited by 23
“Current therapies based on inhibitors of BCRABLp210 fail to eradicate leukemic stem cells, because these cells are not oncogene-addicted.(16,24) Our results indicate that they are susceptible is accompanied by apoptosis of Sca1 cells, which are the cells responsible for cancer maintenance.”
BackgroundMethodIshii, Y., Nhiayi, M. K., Tse, E. S., Cheng, J. D., Massimino, M., Durden, D. L., Vigneri, P. G., & Wang, J. Y. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140585 · Cited by 24
“The resistance of CML cells to TKI can also occur through protection by survival factors and cytokines [14, 18].”
BackgroundThielen, N., Richter, J., Baldauf, M., Barbany, G., Fioretos, T., Giles, F. J., Gjertsen, B. T., Hochhaus, A., Schuurhuis, G. J., Sopper, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2791 · Cited by 23
“LSCs in CML are quiescent, self-renewing cells that derive from nHSCs after acquiring the chromosomal translocation t(9;22) (q34;q11).”
BackgroundTusa, I., Cheloni, G., Poteti, M., Gozzini, A., DeSouza, N. H., Shan, Y., Deng, X., Gray, N. S., Li, S., Rovida, E., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.08.016 · Cited by 26
“In view of a possible therapeutic use of ERK5 pathway inhibitors, it was necessary to evaluate if XMD8-92 maintained the capacity to suppress CML progenitor cell potential when combined with the standard TKi treatment (Figure 5).”
BackgroundInfluentialGajski, G., Gerić, M., Domijan, A., Golubović, I., & Garaj‐Vrhovac, V. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.10.005 · Cited by 25
“Nevertheless, CML stem cells are not as sensitive towards an IM-induced apoptotic effect, despite BCR-ABL activity being inhibited (Barnes and Melo, 2003; Buchdunger et al., 2000; Corbin et al., 2011; Deininger et al., 2005, 1997; Goldman and Melo, 2003; Stagno et al., 2016).”
The RARγ Oncogene: An Achilles Heel for Some Cancers
Brown, G., & Petrie, K. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073632 · Cited by 25
“CML LSCs have also been found to be resistant in vitro to the tyrosine kinase inhibitors, such as imatinib, that are used to treat CML and many different types of cancer [4,5].”
BackgroundAcute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms
Czader, M., & Orazi, A. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpzqk40jozzzcc · Cited by 23
Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance
Rudich, A., Garzon, R., & Dorrance, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012271 · Cited by 25
“CML LSCs also provide a therapeutic challenge as they are not dependent on BCR::ABL1 for survival and therefore cause relapse after treatment discontinuation [45].”
BackgroundJamal, A., Dalhat, M. H., Jahan, S., Choudhry, H., & Khan, M. I. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103569 · Cited by 25
Novel treatment strategies for chronic myeloid leukemia
Cruz‐Rodriguez, N., & Deininger, M. W. (2024) · Blood · doi:10.1182/blood.2024026312 · Cited by 28
Self-citationWeber, A., Borghouts, C., Brendel, C., Moriggl, R., Delis, N., Brill, B., Vafaizadeh, V., & Groner, B. (2015) · Cancers · doi:10.3390/cancers7010503 · Cited by 24
“This might be based on the observation that the survival of CML stem cells, responsible for residual disease in patients, is not dependent on the activity of Bcr-Abl [100,101].”
STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia
Eiring, A. M., Kraft, I. L., Page, B. D. G., O’Hare, T., Gunning, P. T., & Deininger, M. W. (2014) · Leukemia Supplements · doi:10.1038/leusup.2014.3 · Cited by 23
Self-citationPerrotti, D., Silvestri, G., Stramucci, L., Yu, J. E., & Trotta, R. (2016) · Current Drug Targets · doi:10.2174/1389450117666160615074120 · Cited by 25
“While BCR-ABL1 expression but not its activity represents a key factor allowing the acquisition and maintenance of the leukemic CD34+/CD38− LSC phenotype [46-48], it is unclear whether Perrotti et al.”
BackgroundPharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia
Nath, A., Wang, J., & Huang, R. S. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0292-x · Cited by 22
Lu, T., Wei, D., Yu, K., Ma, D., Xiong, J., Fang, Q., & Wang, J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14298 · Cited by 22
In Search of CML Stem Cells’ Deadly Weakness
Pellicano, F., Sinclair, A., & Holyoake, T. L. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0085-y · Cited by 23
Sarkaria, S. M., Decker, M., & Ding, L. (2018) · BioEssays · doi:10.1002/bies.201700190 · Cited by 24
Kaehler, M., Dworschak, M., Rodin, J. P., Ruemenapp, J., Vater, I., Penas, E. M. M., Liu, C., Cascorbi, I., & Nagel, I. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.05.006 · Cited by 24
Zhao, H., & Deininger, M. W. (2023) · Blood · doi:10.1182/blood.2022017152 · Cited by 23
Self-citationCruz-Rodríguez, N., Tang, H., Bateman, B., Tang, W., & Deininger, M. W. (2024) · Leukemia · doi:10.1038/s41375-024-02365-w · Cited by 25
Self-citationTabone‐Eglinger, S., Sollet, Z. C., Pinon, P., Aebischer, N., Wehrle‐Haller, M., Jacquier, M., Boettiger, D. E., & Wehrle‐Haller, B. (2014) · The FASEB Journal · doi:10.1096/fj.14-249425 · Cited by 22
“geting the kinase activity of c-abl and c-kit, CML stem cells are not inhibited by imatinib treatment and persist in the bone marrow, in order to relapse on discontinuation of treatment (7).”
BackgroundSbarba, P. D., Rovida, E., Marzi, I., & Cipolleschi, M. G. (2014) · Hypoxia · doi:10.2147/hp.s51812 · Cited by 24
“The “ischemic” niche would represent the site of Bcr/Abl-independent self-renewal as well as of the maintenance of dynamic, IM-resistant MRD. Moving from these sites to neighboring areas where oxygen tension is still low but glucose concentration is higher (the “hypoxic” niche), LSCs would undergo the rescue of Bcr/Ab…”
InfluentialJia, Q., Sun, H., Xiao, F., Yan, S., Li, Q., Zhang, X., Yang, S., Wang, H., Wang, H., Yang, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.144 · Cited by 21
“However, the insensitivity and resistance of leukemia stem cells to TKI are still the major relapse roots of CML [3].”
BackgroundFlis, S., Bratek, E., Chojnacki, T., Piskorek, M., & Skórski, T. (2019) · Cancers · doi:10.3390/cancers11101544 · Cited by 23
Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
Saifullah, H. H., & Lucas, C. (2021) · Cancers · doi:10.3390/cancers13164175 · Cited by 23
“In vitro experiments reported that LSCs are resistant to TKI therapy, and haematopoietic stem cells (CD34+/CD38-cells) do not solely depend on BCR–ABL1 for survival [7,56].”
BackgroundThe matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia
Suresh, S., McCallum, L. M. R., Crawford, L., Lu, W. H., Sharpe, D. J., & Irvine, A. E. (2013) · The Journal of Pathology · doi:10.1002/path.4246 · Cited by 23
“TKIs can inhibit BCR-ABL activity in CML stem cells but these cells are not addicted to BCR-ABL and BCR-ABL inhibition does not eradicate the leukaemic clone [6].”
BackgroundRegulation of Stem Cell Self-Renewal and Oncogenesis by RNA-Binding Proteins
Hattori, A., Buac, K., & Ito, T. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-29073-7_7 · Cited by 23
Hu, J., Feng, M. H., Liu, Z., Liu, Y., Huang, Z., Li, H., & Feng, W. (2016) · Tumor Biology · doi:10.1007/s13277-016-5413-3 · Cited by 21
Chen, M., Turhan, A. G., Ding, H., Lin, Q., Meng, K., & Jiang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18216 · Cited by 21
“In addition, most patients harbor residual leukemic stem cells (LSCs), which are known to be genetically unstable and less responsive to TKI treatments [19-21, 28-30].”
BackgroundHow I treat newly diagnosed chronic myeloid leukemia in 2015
Gambacorti-Passerini, C. B., & Piazza, R. (2014) · American Journal of Hematology · doi:10.1002/ajh.23887 · Cited by 20
“them, biologically refractory to BCR-ABL inhibition [36,37], and”
BackgroundLao, C., Zheng, P., Chen, H., Liu, Q., An, F., & Zhao, L. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05723-8 · Cited by 23
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
Jabbour, E. J., Haddad, F., Sasaki, K., Carter, B. Z., Alvarado, Y., Nasnas, C. C., Nasr, L. F., Masárová, L., Daver, N. G., Pemmaraju, N., et al. (2024) · Cancer · doi:10.1002/cncr.35317 · Cited by 22
“21,22 26 Using cytometry by time of flight (CyTOF) in a transgenic mouse model, Carter and colleagues 27 showed an increased BCL ‐ 2 expression at the protein level in the bone marrow of inducible CML in mice, particularly in Lin − Sca ‐ Targeting BCL ‐ 2 with venetoclax, in combination with TKIs,…”
Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype
Ravasio, R., Ceccacci, E., & Minucci, S. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.04.002 · Cited by 20
“Chronic myeloid leukemia (CML) is one of the best-described examples, being CML stem cells resistant to Imatinib treatment, in contrast to the dramatic sensitivity of bulk CML cells [48].”
BackgroundSubramaniam, A., Pattnayak, N. C., & Chakraborty, S. (2016) · Scientific Reports · doi:10.1038/srep32493 · Cited by 20
“This phenomenon was already observed by others and it was proposed that these cells do not depend on BCR-ABL kinase activity for their survival and growth factors can stimulate alternative survival signaling pathways 7,8,17,18 .”
Cancer as an ecomolecular disease and a neoplastic consortium
y Cajal, S. R., Capdevila, C., Hernández‐Losa, J., Mattos‐Arruda, L. D., Ghosh, A., Lorent, J., Larsson, O. S., Aasen, T., Postovit, L.-M. M., & Topisirović, I. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.004 · Cited by 22
“This leads to residual disease persistence in patients treated with imatinib, highlighting the importance of understanding epigenetic heterogeneity for the success of the anticancer treatment (52,53).”
BackgroundInoue, A., Kobayashi, C. I., Shinohara, H., Miyamoto, K., Yamauchi, N., Yuda, J., Akao, Y., & Minami, Y. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2519-y · Cited by 20
Li, Y., Hu, J., Song, H., & Wu, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.183 · Cited by 20
Sheng, Y., Ji, Z., Zhao, H., Wang, J., Cheng, C., Xu, W., Wang, X., He, Y., Liu, K., Li, L., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12611 · Cited by 20
“1 Resulting from a t(9,22) (q34;q11) chromosome translocation, the oncogene en‐ codes a chimeric oncoprotein with constitutive tyrosine kinase activity.”
BackgroundZhang, J., Zhang, Y., Cheng, L., Li, C., Dai, L., Zhang, H., Yan, F., Shi, H., Dong, G., Ning, Z., et al. (2018) · Europe PMC (PubMed Central) · Cited by 20
Recent advances in understanding chronic myeloid leukemia: where do we stand?
Kumar, R., & Krause, D. S. (2021) · Faculty Reviews · doi:10.12703/r/10-35 · Cited by 23
Zhao, H., Pomicter, A. D., Eiring, A. M., Franzini, A., Ahmann, J. M., Hwang, J. Y., Senina, A. V., Helton, B., Iyer, S. M., Yan, D., et al. (2021) · Blood · doi:10.1182/blood.2021011802 · Cited by 20
Self-citationKamachi, K., Ureshino, H., Watanabe, T., Yoshida, N., Yamamoto, Y., Kurahashi, Y., Fukuda‐Kurahashi, Y., Hayashi, Y., Hirai, H., Yamashita, S., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.032 · Cited by 21
Elgehama, A. M., Chen, W., Pang, J., Mi, S., Li, J., Guo, W., Wang, X., Gao, J., Yu, B., Shen, Y., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.014 · Cited by 20
Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML
Toda, J., Ichii, M., Oritani, K., Shibayama, H., Tanimura, A., Saito, H., Yokota, T., Motooka, D., Okuzaki, D., Kitai, Y., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01387-9 · Cited by 20
Insights Into Bone Marrow Niche Stability: An Adhesion and Metabolism Route
Ashok, D., Polcik, L., Prosseda, S. D., & Hartmann, T. N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.798604 · Cited by 21
“Myeloid leukemia (CML and AML) is particularly faced with the challenge of targeting cells that are treatment-resistant due to the large repertoire of mutations that arise, namely, point-mutations associated with BCR-ABL in CML or FLT3-TKD in AML (Corbin et al., 2011; Hamilton et al., 2012).”
BackgroundWarfvinge, R., Ulfsson, L. G., Dhapola, P., Safi, F., Sommarin, M. N. E., Soneji, S., Hjorth‐Hansen, H., Mustjoki, S. M., Richter, J., Thakur, R. K., et al. (2024) · eLife · doi:10.7554/elife.92074.3 · Cited by 24
Fenretinide Targets Chronic Myeloid Leukemia Stem/Progenitor Cells by Regulation of Redox Signaling
Du, Y., Xia, Y., Pan, X., Chen, Z., Wang, A., Wang, K., Li, J., & Zhang, J. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4935 · Cited by 20
“The Ki-67 protein is exclusively expressed in proliferative cells and whose negativity is considered quiescence in CML (7).”
InfluentialMechanisms underlying the heterogeneity of myelodysplastic syndromes
Dussiau, C., & Fontenay, M. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.10.004 · Cited by 23
“In BCR-ABL280 driven chronic myeloid leukemia (CML), the initiating cell derives from the HSC compartment 281 and drives the relapse (60,61).”
BackgroundHerrmann, O., Kuepper, M. K., Bütow, M., Costa, I. G., Appelmann, I., Beier, F., Luedde, T., Braunschweig, T. A., Koschmieder, S., Brümmendorf, T. H., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5871-2 · Cited by 23
Truitt, L., Hutchinson, C., DeCoteau, J. F., & Geyer, C. R. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.37 · Cited by 19
Mancini, M., Santis, S. D., Monaldi, C., Bavaro, L., Martelli, M., Castagnetti, F., Gugliotta, G., Rosti, G., Santucci, M. A., Martinelli, G., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1197-9 · Cited by 21
Bernardo, P. S., Lemos, L. G. T., de Moraes, G. N., & Maia, R. C. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100671 · Cited by 19
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
Ng, J. J., & Ong, S. T. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00679-z · Cited by 18
Using functional genomics to overcome therapeutic resistance in hematological malignancies
Calderon, F. A., Gregory, M. A., & DeGregori, J. V. (2012) · Immunologic Research · doi:10.1007/s12026-012-8353-z · Cited by 19
“While the treatment of chronic myeloid leukemia (CML) with BCR-ABL tyrosine kinase inhibitors, like imatinib mesylate, has revolutionized CML therapy and can effectively control the disease in its chronic phase, most patients will require lifetime therapy, as leukemia stem cells persist in most patients [14, 15].”
Cerveira, N., Loureiro, B., Bizarro, S., Correia, C., Torres, L., Lisboa, S., Vieira, J., Santos, R., Pereira, D., Moreira, C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5167-y · Cited by 18
Energy metabolism and drug response in myeloid leukaemic stem cells
Bencomo-Alvarez, A. E., Rubio, A. J., Gonzalez, M. A., & Eiring, A. M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16074 · Cited by 20
“However, these drugs do not target the CML LSC (Graham et al, 2002; Corbin et al, 2011; Hamilton et al, 2012), and the CML clone can rapidly return after treatment is discontinued, even after many years of therapy.”
BackgroundMalyukova, A., Ujvári, D., Yektaei‐Karin, E., Zovko, A., Madapura, H. S., Keszei, M., Nagy, N., Lotfi, K., Björn, N., Wallvik, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04154-0 · Cited by 18
“MCL1 expression can be upregulated in CML cells either by BCRABL1 signaling [9] or potentially by the microenvironment, mainly through signaling of the cytokine receptors which play an important role in the TKI resistance of CD34+ CML stem/ progenitor cells [35, 36].”
BackgroundStuckey, R., Rodríguez, J. F. L., & Gómez‐Casares, M. T. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01228-w · Cited by 20
Lee, Y., Chen, C., Liu, F.-H., Huang, Y.-W., & Huang, H.-M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061939 · Cited by 22
“Several studies reported that patients treated with imatinib still expressed Bcr-Abl despite inhibition of this kinase activity in CML stem/progenitor cells [34,35] and in vitro study [36].”
BackgroundPoint: Cancer Stem Cells—The Evidence Accumulates
Azizi, E., & Wicha, M. S. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.195990 · Cited by 18
Understanding cancer from the stem cells up
Eide, C. A., & Druker, B. J. (2017) · Nature Medicine · doi:10.1038/nm.4353 · Cited by 18
Self-citationGonzález‐Herrero, I., Rodríguez-Hernández, G., Luengas‐Martinez, A., Isidro-Hernández, M., Jiménez, R., Cenador, M. B. G., García‐Criado, F. J., Sánchez-García, I., & Vicente‐Dueñas, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051494 · Cited by 19
The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox
Allegra, A., Innao, V., Tartarisco, G., Pioggia, G., Casciaro, M., Musolino, C., & Gangemi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205226 · Cited by 18
“In AML patients, chromosomal abnormalities have been reported.”
BackgroundInfluentialThe new advance of SALL4 in cancer: Function, regulation, and implication
Abouelnazar, F. A., Zhang, X., Wang, M., Zhang, J., Yu, D. B., Zang, X., Zhang, J., Li, Y., Xu, J., Yang, Q., et al. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24927 · Cited by 20
Askmyr, M., Ågerstam, H., Lilljebjörn, H., Hansen, N., Karlsson, C., von Palffy, S., Landberg, N., Högberg, C., Lassen, C., Rissler, M., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.89 · Cited by 18
“3 As a result, the chronic phase (CP) may transform into a more aggressive form of the disease termed blast crisis (BC), resembling either acute myeloid or B-cell leukemia, a state associated with a high mortality rate.”
BackgroundBreccia, M., & Alimena, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.021 · Cited by 17
Okabe, S., Tanaka, Y., Moriyama, M., & Gotoh, A. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04022-x · Cited by 17
Spinler, K. R., Bajaj, J., Ito, T., Zimdahl, B., Hamilton, M., Ahmadi, A., Koechlein, C. S., Lytle, N. K., Kwon, H. Y., Anower-E-Khuda, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19782-x · Cited by 20
Liu, N., Li, P., Zang, S., Liu, Q., Ma, D., Sun, X., & Ji, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116880 · Cited by 17
“An increasing body of work suggested that disease relapse upon cessation of TKI therapy could be due to CML stem cells, which were resistant or refractory to treatment [10].”
BackgroundIGF-IR determines the fates of BCR/ABL leukemia
Xie, J., Chen, X., Zheng, J., Li, M., Stacy, S., Holzenberger, M., Hu, X., & Zhang, C. C. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0106-8 · Cited by 17
“CMLinitiating cells (CML-ICs) in patients have been shown to be insensitive to TKIs [10].”
BackgroundInfluentialShimasaki, K., Watanabe‐Takahashi, M., Umeda, M., Funamoto, S., Saito, Y., Noguchi, N., Kumagai, K., Hanada, K., Tsukahara, F., Maru, Y., et al. (2017) · Genes to Cells · doi:10.1111/gtc.12544 · Cited by 17
STAT5 and STAT5 Inhibitors in Hematological Malignancies
Tolomeo, M., Meli, M., & Grimaudo, S. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190906160848 · Cited by 18
Pietarinen, P. O., Eide, C. A., Ayuda-Durán, P., Potdar, S., Kuusanmäki, H., Andersson, E. I., Mpindi, J. P., Pemovska, T., Kontro, M., Heckman, C. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15146 · Cited by 16
Self-citationEffect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells
Charaf, L., Mahon, F.-X., Lamrissi-Garcia, I., Moranvillier, I., Beliveau, F., Cardinaud, B., Dabernat, S., de Verneuil, H., Moreau-Gaudry, F., & Bedel, A. (2017) · Leukemia · doi:10.1038/leu.2016.154 · Cited by 16
Gonzalez, M. A., Olivas, I. M., Bencomo-Alvarez, A. E., Rubio, A. J., Barreto‐Vargas, C., López, J. L. G., Dang, S. K., Solecki, J. P., McCall, E. B., Astudillo, G. E., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1146 · Cited by 18
Self-citationBusch, C., Mulholland, T., Zagnoni, M., Dalby, M. J., Berry, C. C., & Wheadon, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01363-2 · Cited by 18
“This upregulation could be the result of targeting progenitor cells [48] and the consequent selection for more primitive cells that entered a quiescent state to prevent apoptosis [7, 49].”
BackgroundTyrosine kinase inhibitors in cancers: Treatment optimization – Part I
Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tétu, P., Lebbé, C., Ciccolini, J., Meyer, N., & Paci, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104384 · Cited by 18
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.